Skip to main content
Log in

Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products: An Overview of the PQRI Recommendations

  • Commentary
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The Product Quality Research Institute Leachables and Extractables Working Group includes pharmaceutical development scientists representing industry, government, and academia. The Working Group was created and constituted to address scientific and regulatory questions concerning the pharmaceutical development process for Orally Inhaled and Nasal Drug Products (OINDP) related to organic extractables and leachables. This effort has resulted in the creation of a detailed “Recommendation Document”, which was submitted to the U.S. FDA for consideration in September 2006. The recommendations include proposed safety and analytical thresholds for leachables and extractables, as well as detailed “best practice” recommendations for various aspects of the OINDP pharmaceutical development process, including: materials selection for OINDP container closure system components, Controlled Extraction Studies, Leachables Studies, and Routine Extractables Testing. The Working Group’s processes and the detailed and comprehensive recommendations that resulted from those processes, demonstrate that the Product Quality Research Institute collaborative process can result in consensus science-based and data driven recommendations that could have a positive effect on patient care. It is anticipated that the Working Group’s recommendations will also contribute to the new “Quality by Design” pharmaceutical development paradigm. This commentary summarizes the best practice recommendations within the context of an overall pharmaceutical development process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. D. Ball, J. Blanchard, D. Jacobson-Kram, R. McClellan, T. McGovern, D. L. Norwood, M. Vogel, R. Wolff, and L. Nagao. Development of safety qualification thresholds and their use in drug product evaluation. Toxicol. Sci. 97(2):226–236 (2007).

    Article  PubMed  CAS  Google Scholar 

  2. IPAC-RS. Good manufacturing practices guideline for suppliers of components for orally inhaled and nasal drug products. International Pharmaceutical Aerosol Consortium on Regulation and Science(2006).

  3. D. L. Norwood. Understanding the challenges of extractables and leachables for the pharmaceutical industry—safety and regulatory environment for pharmaceuticals. Am. Pharm. Rev. 10(2):32–39 (2007).

    Google Scholar 

Download references

Acknowledgements

The authors thank the members of the PQRI Leachables and Extractables Working Group for their hard work and commitment in developing the Recommendations; and the PQRI Steering Committee, PQRI Drug Product Technical Committee, and the IPAC-RS Board of Directors for support of this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lee M. Nagao.

Additional information

The views expressed in this document are not necessarily those of the U.S. Food and Drug Administration.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norwood, D.L., Paskiet, D., Ruberto, M. et al. Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products: An Overview of the PQRI Recommendations. Pharm Res 25, 727–739 (2008). https://doi.org/10.1007/s11095-007-9521-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-007-9521-z

Key words

Navigation